AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

October 11, 2022 | Last Trade: US$3.57 0.06 1.71

AbCellera (Nasdaq: ABCL) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Stock Quote

Last Trade:	US$3.57
Daily Change:	0.06 1.71
Daily Volume:	6,704,974
Market Cap:	US$1.070B

November 10, 2025 AbCellera Appoints Dr. Stephen Quake to its Board of Directors November 06, 2025 AbCellera Reports Q3 2025 Business Results August 27, 2025 AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 August 07, 2025 AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms May 30, 2025 AbCellera Biologics Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE